Respironics, Inc. Fact Sheet

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serves the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics programs help manage sleep-disordered breathing, chronic obstructive pulmonary disease, asthma, infant care, and restrictive lung disorders.

Founded 1976

Our Vision To be the worldwide leader at anticipating needs and providing valued solutions to the sleep and respiratory markets.

Headquarters Respironics, Inc.- Pittsburgh (Murrysville), Pennsylvania, USA

U.S. Facilities Carlsbad, California; Kennesaw, Georgia; Wallingford, Connecticut; Parsippany, New Jersey

Employees More than 5,300 associates worldwide

Key Personnel Gerald E. McGinnis, Chairman of the Board
John L. Miclot, President and Chief Executive Officer
Craig B. Reynolds, Executive Vice President and Chief Operating Officer
Daniel J. Bevevino, Vice President and Chief Financial Officer

Business Groups Sleep and Home Respiratory Group
Hospital Group
International Group

Revenues (FY07) $1.195 billion

Ticker Symbol NASDAQ/NMS Symbol: RESP

Innovations
- Released the world’s first commercial continuous positive airway pressure (CPAP) system in 1985 and the first bi-level continuous positive airway pressure (BiPAP®) unit in 1989
- Received the U.S. patent for bi-level technology in 1992
- Technological “firsts” include:
  - REMstar® Pro 2 with C-Flex™ combines the comfort of C-Flex™ and optional integrated humidifications with the power of Encore® Pro Data Management Software
  - BiliChek® Noninvasive Bilirubin Analyzer predicts bilirubin levels which cause jaundice
  - BiPAP® Vision Ventilatory Support System, a versatile, simple, noninvasive ventilation designed with advanced technology to be accurate, reliable and easily upgradeable
  - Adaptive Aerosol Delivery® technology delivers drugs via the respiratory pathway

12-2007
Financial Highlights

**Revenues & Net Income**


- Record financial success with FY 2007 revenues totaling $1.195 billion
- Met or exceeded earnings expectations for 31 consecutive quarters (quarter ended 6/30/07)
- Research & Development: $64.984 million, excluding stock compensation expenses (5% of net sales)

**Investor information**

*Trading:* The Company’s shares are traded on the over-the-counter market and are reported on the NASDAQ National Market System under the symbol RESP. The Company began trading on the national over-the-counter market on May 12, 1988.
Revenues By Group

International
$102,677
33%

Domestic Sleep and Home Respiratory Group
$160,762
52%

Domestic Hospital Group
$48,199
15%

As of 9/30/07
Dollars in Thousands
Sleep and Home Respiratory Group

Donald J. Spence, President

Home Respiratory Care

Respironics’ Home Respiratory Care Business Unit provides solutions for patients who suffer from chronic respiratory diseases by offering a broad range of oxygen, ventilation and monitoring products. Home Respiratory Care helps clinicians manage respiratory diseases in a transitional care or home environment, and is dedicated to improving respiratory technologies, while leading the research and development of emerging therapies.

Sleep Disordered Breathing

The Sleep market is the cornerstone of Respironics’ business strategy. A recognized global market leader and innovator in the sleep-disordered breathing marketplace, Respironics leverages its core expertise in treating Obstructive Sleep Apnea (OSA) to develop innovative solutions for the diagnosis, treatment and monitoring of other sleep disorders.

Sleep Well Ventures

Sleep Well Ventures moves Respironics beyond its core Obstructive Sleep Apnea (OSA) business into the broader sleep market, which encompasses undiagnosed and untreated sleep and sleep-related movement disorders such as insomnia, circadian rhythm disorders, or restless legs syndrome.

Sleep Well Ventures also works to identify and provide solutions for millions of “problem sleepers” like the chronic snorer or people who have difficulty falling asleep occasionally. The Business Unit seeks to offer sleep professionals, clinicians and their patients solutions that help to improve quality of life through quality sleep.
Hospital Group

Derek Smith, President

Children’s Medical Ventures (ChMV)

Children’s Medical Ventures is the leading provider of developmentally supportive products for premature babies and ill infants offering apnea monitors and recorders, state-of-the-art diagnostic and treatment tools for jaundice, and a line of specialty products that enhance infant growth and development. The business promotes education and hands-on programs for neonatal nurses and works with parents and caregivers to understand the unique requirements of premature and ill infants. Children’s Medical Ventures Business Unit helps extend the company’s reach in hospital Neonatal Intensive Care Units (NICUs) and in the home.

Critical Care

Respironics’ Critical Care offers a unique platform for managing respiratory patients in a variety of medical environments. Through its Total Ventilation Solutions℠ program, Critical Care gives healthcare providers a diverse and innovative portfolio of invasive and noninvasive ventilators, patient masks, accessories and patient monitoring technologies to help treat, monitor and manage respiratory-impaired patients throughout their diseases.

From pre-hospital admission to long-term acute treatment, Respironics leverages its core expertise and leadership in noninvasive ventilation to assist caregivers in avoiding intubation whenever possible, helping to reduce the patient’s risk of infection and to shorten hospitalization.

Respiratory Drug Delivery (RDD)

Respironics is exploring enhanced methods of delivering drugs via the respiratory pathway to help treat chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, cystic fibrosis and conditions beyond respiratory ailments that would benefit from direct, aerosol delivery methods. Respironics’ unique proprietary technology—Adaptive Aerosol Delivery℠—is being integrated into products released in the European and US markets.
International Group

Geoffrey C. Waters, President

International growth is a key component of Respironics' strategic plan. Targeted international acquisitions, investments in the company's international sales and marketing infrastructure, and strong distribution channels have increased Respironics' presence in the global sleep and respiratory marketplace.

Respironics markets its products in 141 countries and has a direct presence in several European countries, Japan and China with initiatives in place for further expansion.

International represents 33 percent of total revenues (1Q08).
Acquisitions, Mergers and Joint Ventures

1995  Respironics acquires Vitalog Monitoring, Inc.; a privately held California-based designer, manufacturing, and marketer of sleep monitoring and diagnostic equipment.


1997  Respironics acquires Stimotron; a distributor in Germany.

1998  Respironics acquires Healthdyne Technologies and, with it, HealthScan Products; a manufacturer and marketer of asthma and allergy devices.

Apr 2002  Respironics acquires Novametrix; a leading cardiorespiratory monitoring company and Children’s Medical Ventures; a leader in developmental care products for premature and ill newborns.

May 2002  Respironics acquires Fuji RC Co. Ltd.; a leading provider of homecare and hospital products and services for respiratory impaired patients in Japan.

Mar 2004  Respironics acquires Caradyne of Galway, Ireland; manufactures and markets unique ventilation and humidification technology.

Jul 2004  Respironics acquires Profile Therapeutics, plc; develops and commercializes specialty products to improve the treatment of sleep and respiratory patients.

Dec 2004  Respironics announces establishment of a Switzerland based subsidiary, Respironics Switzerland, GmbH. The subsidiary will hold majority shares in Pilger Homecare, GmbH and will enable Respironics to participate directly in the Swiss homecare market.

  Respironics purchases part of the Markos Mefar business unit that had been Respironics’ exclusive Italian distributor. As a result, the Company establishes a new distribution subsidiary in Europe called Respironics Italy.

Apr 2005  Respironics acquires Mini-Mitter Company, Inc.; develops and sells sleep and physiological monitoring products to commercial sleep laboratories and other medical, pharmaceutical and health research institutions involved in clinical trials.

Apr 2006  Respironics acquires OxyTec Medical Corporation and its new portable oxygen concentrator. The device has been developed to improve the lives of the growing number of highly ambulatory patients reliant on long-term oxygen therapy, such as those people with chronic obstructive pulmonary disease.
May 2006   Respironics acquires infant products and temperature trend indicator lines of business from **Omni Therm, Inc.** These highly-specialized items have been primarily developed for the NICU and help to expand the growing catalog of Children’s Medical Venture’s products.

Jul 2006   Respironics acquires a majority interest in **Normed AS** based in Oslo, Norway, enhancing its position in the broader Scandinavian geographic market. This investment secures a direct presence for Respironics in the Norwegian market and strengthens the Company’s presence in critical care, homecare and respiratory drug delivery.

Jan 2007   Respironics acquires the homecare business of **Mayo Healthcare**, our long time distributor in this country, to form Respironics Australia. Australia is a key market which offers a unique opportunity for Respironics to successfully deliver solutions to patients who suffer from sleep and respiratory disorders.

Apr 2007   Respironics acquires a majority interest in **Spiropharma AS** based in Copenhagen, Denmark. This investment secures a direct presence in the Danish market and provides access to Spiropharma’s hospital customers in Denmark where hospitals serve as home care providers. This acquisition strengthens our presence in critical care, homecare, and respiratory drug delivery and our position in the broader Scandinavian market.

Apr 2007   Respironics acquires the assets of the **J. H. Emerson Company** to expand our home respiratory care product portfolio and enable us to better serve the needs of respiratory impaired patients in the home.

Oct 2007   Respironics acquires 100% of the outstanding shares of **Apollo Light Systems, Inc.**, a leading manufacturer of light therapy systems for melatonin suppression and circadian rhythm sleep disorders. Apollo light therapy technologies further our strategy to expand into the broader sleep market.

Dec 2007   Respironics acquires **Pro-Tech Services, Inc.**, a leading Seattle-based manufacturer of sensors for the sleep diagnostic market. The addition of Pro-Tech expands our diagnostic product portfolio and enables us to better serve the needs of our sleep lab customers.
Awards & Recognitions

1988  America's 500 Fastest Growing Private Companies, Inc. magazine, Ranked 457
1988  Governor's New Product Award: SleepEasy® II Nasal CPAP System
1990  200 Best Small Companies in America, Forbes magazine, Ranked 35
1990  Top 10 Pittsburgh Growth Companies, Executive Report magazine, Ranked 6
1991  American Association for Respiratory Care Zenith Award, First Award
1991  200 Best Small Companies in America, Forbes magazine, Ranked 62
1991  Governor's New Product Award: BiPAP® Ventilator Mask
1993  American Association for Respiratory Care Zenith Award, Second Award
1994  American Association for Respiratory Care Zenith Award, Third Award
1996  200 Best Small Companies in America, Forbes magazine, Ranked 159
1996  American Association for Respiratory Care Zenith Award, Fourth Award
1997  200 Best Small Companies in America, Forbes magazine, Ranked 179
1998  American Association for Respiratory Care Zenith Award, Fifth Award
1999  American Association for Respiratory Care Zenith Award, Sixth Award
2002  200 Best Small Companies in America, Forbes magazine, Ranked 135
2002  American Association for Respiratory Care Zenith Award, Seventh Award
2003  American Association for Respiratory Care Zenith Award, Eighth Award
2003  Manager of the Year, John Miclot, Pittsburgh Business Times
2003  Manufacturer of the Year Award, Pittsburgh Business Times
2004  Excellence Entrepreneur Award Carnegie Science Center: Jerry McGinnis
2004  Entrepreneur of the Year Washington & Jefferson College: Jerry McGinnis
2004  Standard of Excellence Award Web Marketing Association: Comfort Series™ site
2004  Pittsburgh Tech 50 Award-Life Sciences Category, Pittsburgh Technology Council
2004  People Do Matter Award-Strategic Alignment, Pittsburgh Technology Council
2004  American Business Ethics Award, Pittsburgh Business Times
2005  100 Fastest Growing Tech Companies, Business 2.0 magazine, Ranked: 85
2005  Top 100 Mid-cap Stocks, Forbes Magazine, Ranked 33
2005  Top 50 Best Places to Work in Western Pa, Pittsburgh Business Times
2005  American Association for Respiratory Care Zenith Award, Ninth Award
2005  Frost & Sullivan Award, Sleep Diagnostic Equipment Quality/Customer Service
2005  CEO of the Year Award: John Miclot, Pittsburgh Tech 50
2005  Impact Company of the Year Award, Junior Achievement
2005  Manufacturer of the Year Award, Pittsburgh Business Times
2005  Pittsburgh 2005 Pacesetters: Jerry McGinnis, Smart Business Pittsburgh magazine
2006  Frost & Sullivan Award, Sleep Diagnostic Marketing
2006  M2M Magazine Value Chain Award, Gold-Healthcare Category
2006  Frost & Sullivan Award, Market Leader Sleep Therapy
2006  Best Plants Finalist in 2006, Industry Week (awards in October)
2006  American Association for Respiratory Care Zenith Award, Tenth Award
2007  Forbes – Platinum 400 Best Big Businesses in America
2007  CEO Communicator of the Year – Public Relations Society of America
2007  Top 100 Businesses in 2006 – Pennsylvania Business Central
2007  Corporate Partner of the Year – Forbes Health Foundation
2007  Medical Design Magazine – Top 21 OEMs
2007  Top 50 Businesses – Pittsburgh Post-Gazette
2007  Forbes – America’s Most Trustworthy Companies (Top 100)
2007  CNBC Fast Money “Streetheart”
2007  Pittsburgh Business Times, Philanthropy’s Heavy Hitters (John Miclot)
2007  Pittsburgh Business Times, Largest Area Public Companies (Rank: 15)
2007  Medtrade Spring Innovation Award (May 2007)
2007  Pittsburgh Business Times, 50 Largest Area Employers (Rank: 41)
2007  Pittsburgh 2007 Pacesetters Finalist – John Miclot, Smart Business Pittsburgh
2007  Pittsburgh Council of International Visitors, International Bridge Awards-Commerce
2007  Top of the Class Award/Sleep Disorders Therapy – Advance for Managers of Respiratory Care readers survey
2007  American Association for Respiratory Care Zenith Award, Eleventh Award

12/20/2007 2:17 PM